Telehealth startup Nurx raised a $22.5 million extension to its Series C round as the company expands its care offerings.
Subscribe to the Crunchbase Daily
Nurx is probably best known for delivering birth control and the HIV-prevention medication PrEP. But it also offers at-home STI testing, treatment for genital and oral herpes, and emergency contraception.
The company is now also expanding into migraine and headache treatment. The new funding will help with that, as Nurx looks to get deeper into areas of health that many people find sensitive, according to CEO Varsha Rao.
“We want to continue to really care for patients in a really holistic way under this umbrella of sensitive health,” Rao said in an interview with Crunchbase News.
The extension round, which closed in May, comes as Nurx has experienced a surge in demand for its health services–especially birth control–amid the COVID-19 pandemic. The company has seen a 75 percent increase in new patient requests (more than 250,000) for birth control since the beginning of this year, according to a statement from Nurx. The company provides its services to more than 300,000 patients every month.
Nurx began conversations to raise more money in early April after seeing the demand for its services surge, Rao said. The company had a path to profitability, but wanted a bit of a cushion. Nurx has reached $150 million for its annual run rate, and expects to be profitable by early next year. Rao declined to disclose valuation.
The company plans on using the new funding to build out its team, and invest in its migraine and headache services.
“Going really deep in these hormonally-related sensitive areas is something we think makes sense and is a really important service, healthcare service to offer patients, especially in this environment,” Rao said, noting how the pandemic’s limitation for in-person care.
Nurx last raised a $32 million Series C in August 2019, per Crunchbase.
Illustration: Dom Guzman
Stay up to date with recent funding rounds, acquisitions, and more with the Crunchbase Daily.